GlassScriptPhysician profile
Frank Morocco
NPI 1659508018
$201,616.62
in general payments reported to CMS, 2019-2025
36 companies · $70K in 2025
The $70K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $1,568 · 2021: $6,356 · 2022: $14K · 2023: $16K · 2024: $71K · 2025: $70K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $121K · Consulting Fee: $18K · Food and Beverage: $13K · Travel and Lodging: $3,179 · Education: $311 · Honoraria: $30.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $121,330.00 |
| Consulting Fee | $18,416.00 |
| Food and Beverage | $12,987.05 |
| Travel and Lodging | $3,179.42 |
| Education | $310.88 |
| Honoraria | $30.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $54,022.86 | 2019-2025 | |
| Amgen INC. | $41,729.35 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $32,696.73 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Abbvie INC. | $28,462.52 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $16,121.45 | 2019-2025 | |
| Genzyme Corporation | $6,740.76 | 2019-2025 | |
| Janssen Biotech, INC. | $5,282.87 | 2019-2025 | Tremfya, Remicade, Stelara |
| Incyte Corporation | $4,478.31 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $3,788.16 | 2019-2025 | Dupixent, Libtayo |
| Ucb, INC. | $1,782.30 | 2019-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $1,384.68 | 2022-2024 | Vtama |
| Lilly USA, LLC | $1,115.77 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $752.22 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Arcutis Biotherapeutics, INC. | $519.30 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $500.83 | 2022-2025 | Sotyktu |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $415.24 | 2019-2024 | Arazlo, Cabtreo |
| Leo Pharma INC. | $266.05 | 2019-2025 | Adbry |
| Genentech USA, INC. | $249.11 | 2019-2025 | Xolair |
| Mayne Pharma Commercial LLC | $243.29 | 2019-2025 | |
| Almirall LLC | $217.94 | 2019-2024 | Klisyri, Seysara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.58 | 2023-2025 | Spevigo, Cyltezo |
| Organon LLC | $117.21 | 2025 | Vtama, Hadlima |
| Journey Medical Corporation | $97.46 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $82.08 | 2019 | |
| Vyne Pharmaceuticals INC. | $70.22 | 2020 | |
| Prugen, INC. Pharmaceuticals | $63.98 | 2019 | |
| Verrica Pharmaceuticals INC. | $57.36 | 2024-2025 | Ycanth |
| Epi Health, LLC | $51.91 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $43.71 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $39.68 | 2019 | |
| Kyowa Kirin, INC. | $21.05 | 2025 | |
| Sandoz INC. | $20.15 | 2023 | Hyrimoz |
| Fresenius Kabi USA, LLC | $17.88 | 2023 | |
| Paratek Pharmaceuticals, INC. | $16.13 | 2025 | Nuzyra |
| Smith+Nephew, INC. | $12.81 | 2019 | |
| Genentech, INC. | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Morocco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.